Prospective Randomized Controlled Trial Comparing MatriDerm Plus Split-Thickness Skin Graft versus Split-Thickness Skin Graft Alone Following Post-Burn Contracture Release: Functional Recovery and Scar Quality Outcomes
International Journal of Current Pharmaceutical Review and Research · 30.06.2026 · 18 (06)
DOI: 10.25258/ijcpr.18.6.225 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Current Pharmaceutical Review and Research, online erschienen am 30.06.2026. Verfasst von Abhinav Mehrotra und 2 weiteren Autor:innen.
Themen: Kontrakturprophylaxe
Abstract (Originalsprache)
Background
Post-burn contractures are a major cause of functional disability and cosmetic deformity following burn injuries. Although split-thickness skin grafting (STSG) after contracture release remains the standard reconstructive procedure, secondary graft contraction and hypertrophic scarring continue to compromise long-term functional and aesthetic outcomes. MatriDerm, an acellular collagen–elastin dermal matrix, has been introduced to promote dermal regeneration and improve reconstructive outcomes.
Methods
This prospective randomized controlled trial included 60 patients with post-burn contractures who were randomly allocated into two groups: MatriDerm + STSG (n = 30) and STSG alone (n = 30). Patients were followed for 12 months. The primary outcomes were scar quality, assessed using the Vancouver Scar Scale (VSS) and the Patient and Observer Scar Assessment Scale (POSAS), and functional recovery measured by joint range of motion (ROM). Secondary outcomes included graft take, wound healing, postoperative complications, contracture recurrence, and patient satisfaction. ± Results: Patients treated with MatriDerm + STSG demonstrated significantly better scar quality, with lower mean VSS scores (4.3 ± 1.5 vs. 6.5 ± 1.8; p < 0.001), greater improvement in joint ROM (89.4 ± 8.6% vs. 75.2 10.4%; p < 0.001), and higher graft take (97.1 ± 2.8% vs. 94.5 ± 4.2%; p = 0.038) compared with the STSGalone group. Contracture recurrence was lower in the MatriDerm group (6.7% vs. 20.0%), while postoperative complication rates were comparable between the two groups. Patient satisfaction scores were significantly higher among patients receiving MatriDerm.
Conclusion
The addition of MatriDerm to split-thickness skin grafting following post-burn contracture release resulted in improved scar quality, enhanced functional recovery, higher patient satisfaction, and reduced contracture recurrence without increasing postoperative complications. These findings suggest that MatriDerm is an effective adjunct to conventional STSG for the reconstruction of post-burn contractures. Further multicentre studies with larger sample sizes and longer follow-up are recommended to confirm these findings.
Zitieren
APA
Mehrotra, A., Shukla, M. K., & Tiwary, S. (2026). Prospective Randomized Controlled Trial Comparing MatriDerm Plus Split-Thickness Skin Graft versus Split-Thickness Skin Graft Alone Following Post-Burn Contracture Release: Functional Recovery and Scar Quality Outcomes. International Journal of Current Pharmaceutical Review and Research, 18(06). https://doi.org/10.25258/ijcpr.18.6.225
Vancouver
Mehrotra A, Shukla MK, Tiwary S. Prospective Randomized Controlled Trial Comparing MatriDerm Plus Split-Thickness Skin Graft versus Split-Thickness Skin Graft Alone Following Post-Burn Contracture Release: Functional Recovery and Scar Quality Outcomes. International Journal of Current Pharmaceutical Review and Research. 2026;18(06). doi:10.25258/ijcpr.18.6.225
BibTeX
@article{Mehrotra2026,
author = {Mehrotra, Abhinav and Shukla, Mithilesh Kumar and Tiwary, Setubandhu},
title = {Prospective Randomized Controlled Trial Comparing MatriDerm Plus Split-Thickness Skin Graft versus Split-Thickness Skin Graft Alone Following Post-Burn Contracture Release: Functional Recovery and Scar Quality Outcomes},
journal = {International Journal of Current Pharmaceutical Review and Research},
year = {2026},
volume = {18},
number = {06},
doi = {10.25258/ijcpr.18.6.225}
}
EUVIMED